CDKN2A and central nervous system cancer: According to the 2021 updates, molecular characteristics such as CDKN2A/B homozygous deletion now play a major role, leading to the reclassification of a subset of IDH-mutant low-grade gliomas as grade 4 tumours, reflecting a more aggressive biological profile [1].